Table 3.
Treatment-related adverse events (n = 22)
| n (%) | All grade | Grade 3/4 |
|---|---|---|
| Hematologic adverse events | ||
| Leukopenia | 19 (86.4) | 6 (27.3) |
| Neutropenia | 20 (90.9) | 7 (31.8) |
| Anemia | 22 (100.0) | 1 (4.5) |
| Thrombocytopenia | 5 (22.7) | 0 (0) |
| Febrile neutropenia | 1 (4.5) | 1 (4.5) |
| Nonhematologic adverse events (≥ 10%) | ||
| Nausea | 18 (81.8) | 0 (0) |
| Vomiting | 4 (18.2) | 0 (0) |
| Constipation | 19 (86.4) | 0 (0) |
| Diarrhea | 5 (22.7) | 0 (0) |
| Stomatitis | 5 (22.7) | 0 (0) |
| Anorexia | 20 (90.9) | 1 (4.5) |
| Fatigue | 15 (68.2) | 1 (4.5) |
| Pain | 6 (27.3) | 0 (0) |
| Fever | 3 (13.6) | 0 (0) |
| Weight loss | 3 (13.6) | 0 (0) |
| Alopecia | 15 (68.2) | 0 (0) |
| Rash | 6 (27.3) | 0 (0) |
| AST increase | 4 (18.2) | 0 (0) |
| ALT increase | 9 (40.9) | 0 (0) |
| ALP increase | 11 (50.0) | 0 (0) |
| Blood bilirubin increase | 4 (18.2) | 0 (0) |
| Creatinine increase | 7 (31.8) | 0 (0) |
| Hypoalbuminemia | 18 (81.8) | 0 (0) |
| Hyperkalemia | 15 (68.2) | 1 (4.5) |
| Hypocalcemia | 4 (18.2) | 0 (0) |
| Hypokalemia | 5 (22.7) | 0 (0) |
| Hyponatremia | 5 (22.7) | 4 (18.2) |
| Peripheral sensory neuropathy | 6 (27.3) | 1 (4.5) |
| Myalgia | 3 (13.6) | 0 (0) |
| Lung infection | 4 (18.2) | 4 (18.2) |
AST aspartate aminotransferase, ALT alanine aminotransferase